Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

35,000 asthma patients under the microscope: Real-World dupilumab use revealed

NCT ID NCT07637292

Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how dupilumab, a drug for severe asthma, is actually used by patients in France. Researchers will analyze health records of about 35,000 people to describe their characteristics, healthcare costs, and steroid use before and after starting the drug. The goal is to understand real-world effectiveness and patterns, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dupilumab
What this could lead to
If successful, this study could provide insights into how dupilumab is used in everyday practice for severe asthma, potentially guiding better treatment decisions.
What could go wrong
This is an observational study analyzing existing data, not a controlled trial. It cannot prove cause and effect, and results may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 35,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

For this study, we will use the data from the SNDS database. This is the French claims database, which contains all information related to public and private healthcare reimbursements from various regimens in France. It includes all non-hospital reimbursed healthcare expenditures. In 2019, SNIIRAM covered 98.8% of the French population. It also contains demographic characteristics (age, sex, vital status), information on healthcare professionals, presence of chronic condition with ICD-10 codes, as well as information on date and nature of medical and paramedical interventions, laboratory tests, medical transportations, and number of days of paid sick leaves. These data are linked to the hospital discharge ICD-10 diagnoses codes for all medical, obstetric, and surgery hospitalizations, medical procedures, hospitalization department, and cost coding system. Data are also linked to the national deaths database for medical causes of death.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * At least one reimbursement of dupilumab during the inclusion period from November 10, 2020 to December 31, 2023 * At least one of the following asthma markers: * at least one reimbursement of inhaled corticosteroids (ICS and fixed-dose combination ICS/LABA inhalers) in a 3-month time-window before and after one of the reimbursement of dupilumab * A Long-Term Disease (LTD) for asthma in the 12 months before dupilumab initiation or over follow-up. * An hospital admission for asthma in the 12 months before dupilumab initiation or over follow-up. Exclusion Criteria: \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asthma acute are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute asthma chronic asthma T2-high asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asthma acute

Contacts and locations

Locations

  • Hospices Civils de Lyon

    Lyon, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.